Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Heidelberg Pharma AGLTS:0QW5 19 EV-to-EBITDA is -3.24 as of Sep. 09, 2026. GuruFocus rates LTS:0QW5 with a GF Score™ of 19/100. The stock has 5 warning signs investors should review. Among 400 Biotechnology companies, Heidelberg Pharma AG ranks worse than 249999.75% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Heidelberg Pharma AG's enterprise value is €94.42 Mil.
Heidelberg Pharma AG's EBITDA for the trailing twelve months (TTM) ended in May. 2026 was €-29.11 Mil. Therefore, Heidelberg Pharma AG's EV-to-EBITDA for today is -3.24.
The historical rank and industry rank for Heidelberg Pharma AG's EV-to-EBITDA or its related term are showing as below:
LTS:0QW5'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.12 Med: -5.62 Max: -1.3
Current: -3.24
During the past 13 years, the highest EV-to-EBITDA of Heidelberg Pharma AG was -1.30. The lowest was -15.12. And the median was -5.62.
LTS:0QW5's EV-to-EBITDA is ranked worse than 100% of 400
companies
in the Biotechnology industry
Industry Median: 13.615
vs LTS:0QW5: -3.24
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Heidelberg Pharma AG (LTS:0QW5) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Heidelberg Pharma AG's PE Ratio (TTM) for today is calculated as:
Heidelberg Pharma AG's share price for today is €2.57.
Heidelberg Pharma AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.711.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Heidelberg Pharma AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0QW5 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Heidelberg Pharma AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Heidelberg Pharma AG EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Heidelberg Pharma AG's EV-to-EBITDA falls into.
Heidelberg Pharma AG's current Enterprise Value is €94.42 Mil.
Heidelberg Pharma AG's EBITDA for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-29.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Heidelberg Pharma AG (LTS:0QW5) has a EV-to-EBITDA of -3.24 as of Sep. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Heidelberg Pharma AG. According to the industry distribution chart, Heidelberg Pharma AG ranks #999999 out of 400 companies in the Biotechnology industry.
Is Heidelberg Pharma AG's EV-to-EBITDA too high?
Heidelberg Pharma AG's current EV-to-EBITDA is -3.24. Based on the distribution chart, Heidelberg Pharma AG ranks #999999 out of 400 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Heidelberg Pharma AG has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Heidelberg Pharma AG ranks #999999 out of 400 companies for EV-to-EBITDA. This places Heidelberg Pharma AG in the lower half of its industry. The industry median EV-to-EBITDA is 13.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.62, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Heidelberg Pharma AG. For the Biotechnology industry, the median EV-to-EBITDA is 13.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Heidelberg Pharma AG's current EV-to-EBITDA is -3.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Heidelberg Pharma AG (LTS:0QW5) has a current EV-to-EBITDA of -3.24. The current EV-to-EBITDA is -3.24. Heidelberg Pharma AG's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Heidelberg Pharma AG (LTS:0QW5), the current EV-to-EBITDA is -3.24 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
19GF Score
Get the complete analysis for LTS:0QW5
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QW5 has been successfully added to your 
